OGEN
Oragenics, Inc.
There isn't enough reported data to score OGEN yet.
OGEN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
OGEN's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
OGEN PE Valuation
OGEN has no meaningful PE right now: it lost money over the past year.
OGEN Forward outlook
There aren't enough analyst estimates for OGEN to show an outlook.
OGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$24.05 | +$185.95 |
| Q2 2025 | -$33.49 | +$190.61 |
| Q1 2025 | -$45.69 | +$208.41 |
| Q4 2024 | -$63.09 | +$212.31 |
| Q3 2024 | -$210.00 | -$63.49 |
| Q2 2024 | -$224.10 | -$49.09 |
| Q1 2024 | -$254.10 | -$70.39 |
| Q4 2023 | -$275.40 | -$61.99 |
OGEN is still losing money, but far less than before: $24.05 per share over the past year, against $918.00 at its worst in mid-2020.
OGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $7.5K | -91% |
| Q2 2023 | $13.2K | -57% |
| Q1 2023 | $17K | +13% |
OGEN's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2023 | -28053% | -23514 points |
| Q2 2023 | -23622% | -11763 points |
| Q1 2023 | -17063% | +13502 points |
| Q3 2022 | -4539% | N/A |
| Q2 2022 | -11859% | N/A |
| Q1 2022 | -30565% | N/A |
OGEN's operating margin was −28053% last quarter, down 16194 points from the same quarter a year ago.
OGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2M | +$951.1K |
| Q2 2026 | -$2.2M | -$872.4K |
| Q1 2026 | -$2.2M | -$88.6K |
| Q4 2025 | -$2.8M | -$817.1K |
| Q3 2025 | -$3M | -$1M |
| Q2 2025 | -$1.3M | +$230.2K |
| Q1 2025 | -$2.1M | +$952.2K |
| Q4 2022 | -$2.4M | -$532.1K |
OGEN has burned cash in almost every quarter: −$9M over the past year, against −$8M the year before.
OGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +83.4K shares |
| 1 year | +517% | +3.8M shares |
| 3 years | +6585% | +4.4M shares |
| 5 years | +7787% | +4.5M shares |
| Available history | +19107% | +4.5M shares |
OGEN has 5M diluted shares, up 517% from a year ago.
OGEN Net Leverage
OGEN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 5.7 | Oversold |
OGEN's weekly RSI is 26 (oversold) and its Stochastic is 6 (oversold).
OGEN PE vs Healthcare Sector
OGEN has no meaningful PE right now: it lost money over the past year.
OGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.42 | 17% below |
| 20 week MA | $0.48 | 27% below |
| 50 week MA | $0.63 | 44% below |
| 100 week MA | $2.60 | 87% below |
| 200 week MA | $41.7 | 99% below |
OGEN is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
OGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $948.6 | $774.0 | -18% |
| 2021 | $774.0 | $867.8 | +12% |
| 2022 | $867.8 | $261.0 | -70% |
| 2023 | $261.0 | $168.9 | -35% |
| 2024 | $168.9 | $13.6 | -92% |
| 2025 | $13.6 | $0.86 | -94% |
| 2026 YTD | $0.86 | $0.35 | -59% |
OGEN has finished four years in a row lower, and it's down 59% so far in 2026.